{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,8,28]],"date-time":"2026-08-28T13:28:27Z","timestamp":1787923707955,"version":"build-2784847793"},"reference-count":24,"publisher":"Elsevier BV","license":[{"start":{"date-parts":[[2026,9,1]],"date-time":"2026-09-01T00:00:00Z","timestamp":1788220800000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"},{"start":{"date-parts":[[2026,9,1]],"date-time":"2026-09-01T00:00:00Z","timestamp":1788220800000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/legal\/tdmrep-license"},{"start":{"date-parts":[[2026,7,5]],"date-time":"2026-07-05T00:00:00Z","timestamp":1783209600000},"content-version":"vor","delay-in-days":0,"URL":"http:\/\/creativecommons.org\/licenses\/by-nc-nd\/4.0\/"}],"content-domain":{"domain":["clinicalkey.com","clinicalkey.com.au","clinicalkey.es","clinicalkey.fr","clinicalkey.jp","msard-journal.com","elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["Multiple Sclerosis and Related Disorders"],"published-print":{"date-parts":[[2026,9]]},"DOI":"10.1016\/j.msard.2026.107379","type":"journal-article","created":{"date-parts":[[2026,7,5]],"date-time":"2026-07-05T22:01:55Z","timestamp":1783288915000},"page":"107379","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":0,"special_numbering":"C","title":["Discontinuing immunotherapy in aquaporin-4-IgG-seropositive neuromyelitis optica spectrum disorder: Relapse risk and disability outcomes after treatment withdrawal"],"prefix":"10.1016","volume":"113","author":[{"ORCID":"https:\/\/orcid.org\/0009-0008-6328-6591","authenticated-orcid":false,"given":"Natapong","family":"Thaneerat","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Jirud","family":"Buranaattachai","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Chatdaw","family":"Lapngampian","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Dachathorn","family":"Tharacheewin","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Tatchaporn","family":"Ongphichetmetha","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Sasitorn","family":"Siritho","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Naraporn","family":"Prayoonwiwat","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Natthapon","family":"Rattanathamsakul","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Onpawee","family":"Sangsai","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Kamonchanok","family":"Aueaphatthanawong","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Jirawan","family":"Budkum","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0003-3342-2755","authenticated-orcid":false,"given":"Jiraporn","family":"Jitprapaikulsan","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"78","reference":[{"key":"10.1016\/j.msard.2026.107379_bib0001","doi-asserted-by":"crossref","first-page":"1352","DOI":"10.1016\/S0140-6736(19)31817-3","article-title":"Inebilizumab for the treatment of neuromyelitis optica spectrum disorder (N-MOmentum): a double-blind, randomised placebo-controlled phase 2\/3 trial","volume":"394","author":"Cree","year":"2019","journal-title":"Lancet"},{"key":"10.1016\/j.msard.2026.107379_bib0002","doi-asserted-by":"crossref","first-page":"588","DOI":"10.1016\/S1474-4422(24)00077-2","article-title":"Safety and efficacy of inebilizumab for the treatment of neuromyelitis optica spectrum disorder: end-of-study results from the open-label period of the N-MOmentum trial","volume":"23","author":"Cree","year":"2024","journal-title":"Lancet Neurol."},{"key":"10.1016\/j.msard.2026.107379_bib0003","doi-asserted-by":"crossref","first-page":"22","DOI":"10.1016\/j.msard.2019.05.011","article-title":"Efficacy and tolerability of azathioprine for neuromyelitis optica spectrum disorder: a systematic review and meta-analysis","volume":"33","author":"Espiritu","year":"2019","journal-title":"Mult. Scler. Relat. Disord."},{"key":"10.1016\/j.msard.2026.107379_bib0004","doi-asserted-by":"crossref","first-page":"2221","DOI":"10.1212\/01.WNL.0000289761.64862.ce","article-title":"Pathogenic potential of IgG binding to water channel extracellular domain in neuromyelitis optica","volume":"69","author":"Hinson","year":"2007","journal-title":"Neurology"},{"key":"10.1016\/j.msard.2026.107379_bib0005","doi-asserted-by":"crossref","first-page":"1128","DOI":"10.1001\/archneurol.2009.175","article-title":"Treatment of neuromyelitis optica with mycophenolate mofetil: retrospective analysis of 24 patients","volume":"66","author":"Jacob","year":"2009","journal-title":"Arch. Neurol."},{"key":"10.1016\/j.msard.2026.107379_bib0006","doi-asserted-by":"crossref","first-page":"149","DOI":"10.1111\/cei.12271","article-title":"Neuromyelitis optica: clinical features, immunopathogenesis and treatment","volume":"176","author":"Jarius","year":"2014","journal-title":"Clin. Exp. Immunol."},{"key":"10.1016\/j.msard.2026.107379_bib0007","doi-asserted-by":"crossref","first-page":"1197","DOI":"10.1212\/WNL.0b013e3182a6cb5c","article-title":"Updated estimate of AQP4-IgG serostatus and disability outcome in neuromyelitis optica","volume":"81","author":"Jiao","year":"2013","journal-title":"Neurology"},{"key":"10.1016\/j.msard.2026.107379_bib0008","doi-asserted-by":"crossref","DOI":"10.1212\/NXI.0000000000000269","article-title":"Early indicators of relapses vs pseudorelapses in neuromyelitis optica spectrum disorder","volume":"3","author":"Kessler","year":"2016","journal-title":"Neurol. Neuroimmunol. Neuroinflamm."},{"key":"10.1016\/j.msard.2026.107379_bib0009","doi-asserted-by":"crossref","DOI":"10.1212\/NXI.0000000000000947","article-title":"Discontinuation of immunosuppressive therapy in patients with neuromyelitis optica spectrum disorder with aquaporin-4 antibodies","volume":"8","author":"Kim","year":"2021","journal-title":"Neurol. Neuroimmunol. Neuroinflamm."},{"key":"10.1016\/j.msard.2026.107379_bib0010","doi-asserted-by":"crossref","first-page":"473","DOI":"10.1084\/jem.20050304","article-title":"IgG marker of optic-spinal multiple sclerosis binds to the aquaporin-4 water channel","volume":"202","author":"Lennon","year":"2005","journal-title":"J. Exp. Med."},{"key":"10.1016\/j.msard.2026.107379_bib0011","doi-asserted-by":"crossref","first-page":"2792","DOI":"10.1111\/ene.15425","article-title":"Immunosuppressant and neuromyelitis optica spectrum disorder: optimal treatment duration and risk of discontinuation","volume":"29","author":"Li","year":"2022","journal-title":"Eur. J. Neurol."},{"key":"10.1016\/j.msard.2026.107379_bib0012","doi-asserted-by":"crossref","first-page":"1450","DOI":"10.1093\/brain\/awf151","article-title":"A role for humoral mechanisms in the pathogenesis of Devic\u2019s neuromyelitis optica","volume":"125","author":"Lucchinetti","year":"2002","journal-title":"Brain"},{"key":"10.1016\/j.msard.2026.107379_bib0013","doi-asserted-by":"crossref","first-page":"727","DOI":"10.1002\/ana.26722","article-title":"Alterations in aquaporin-4-IgG serostatus in 986 patients: a laboratory-based longitudinal analysis","volume":"94","author":"Majed","year":"2023","journal-title":"Ann. Neurol."},{"key":"10.1016\/j.msard.2026.107379_bib0014","doi-asserted-by":"crossref","DOI":"10.1212\/NXI.0000000000000978","article-title":"Disability outcomes in the N-MOmentum trial of inebilizumab in neuromyelitis optica spectrum disorder","volume":"8","author":"Marignier","year":"2021","journal-title":"Neurol. Neuroimmunol. Neuroinflamm."},{"key":"10.1016\/j.msard.2026.107379_bib0015","doi-asserted-by":"crossref","first-page":"324","DOI":"10.1001\/jamaneurol.2013.5699","article-title":"Comparison of relapse and treatment failure rates among patients with neuromyelitis optica: multicenter study of treatment efficacy","volume":"71","author":"Mealy","year":"2014","journal-title":"JAMA Neurol."},{"key":"10.1016\/j.msard.2026.107379_bib0016","doi-asserted-by":"crossref","first-page":"614","DOI":"10.1056\/NEJMoa1900866","article-title":"Eculizumab in aquaporin-4-positive neuromyelitis optica spectrum disorder","volume":"381","author":"Pittock","year":"2019","journal-title":"N. Engl. J. Med."},{"key":"10.1016\/j.msard.2026.107379_bib0017","doi-asserted-by":"crossref","first-page":"1053","DOI":"10.1002\/ana.26626","article-title":"Ravulizumab in aquaporin-4-positive neuromyelitis optica spectrum disorder","volume":"93","author":"Pittock","year":"2023","journal-title":"Ann. Neurol."},{"key":"10.1016\/j.msard.2026.107379_bib0018","doi-asserted-by":"crossref","first-page":"599","DOI":"10.3988\/jcn.2021.17.4.599","article-title":"Relapse after cessation of immunosuppressants in seropositive neuromyelitis optica spectrum disorder with long-term remission","volume":"17","author":"Seok","year":"2021","journal-title":"J. Clin. Neurol."},{"key":"10.1016\/j.msard.2026.107379_bib0019","doi-asserted-by":"crossref","first-page":"402","DOI":"10.1016\/S1474-4422(20)30078-8","article-title":"Safety and efficacy of satralizumab monotherapy in neuromyelitis optica spectrum disorder: a randomised, double-blind, multicentre, placebo-controlled phase 3 trial","volume":"19","author":"Traboulsee","year":"2020","journal-title":"Lancet Neurol."},{"key":"10.1016\/j.msard.2026.107379_bib0020","doi-asserted-by":"crossref","first-page":"1","DOI":"10.1007\/s00415-013-7169-7","article-title":"Update on the diagnosis and treatment of neuromyelitis optica: recommendations of the Neuromyelitis Optica Study Group (NEMOS)","volume":"261","author":"Trebst","year":"2014","journal-title":"J. Neurol."},{"key":"10.1016\/j.msard.2026.107379_bib0021","doi-asserted-by":"crossref","first-page":"663","DOI":"10.1016\/j.mayocp.2016.12.014","article-title":"Neuromyelitis spectrum disorders","volume":"92","author":"Weinshenker","year":"2017","journal-title":"Mayo Clin. Proc."},{"key":"10.1016\/j.msard.2026.107379_bib0022","doi-asserted-by":"crossref","first-page":"177","DOI":"10.1212\/WNL.0000000000001729","article-title":"International consensus diagnostic criteria for neuromyelitis optica spectrum disorders","volume":"85","author":"Wingerchuk","year":"2015","journal-title":"Neurology"},{"key":"10.1016\/j.msard.2026.107379_bib0023","doi-asserted-by":"crossref","first-page":"1107","DOI":"10.1212\/WNL.53.5.1107","article-title":"The clinical course of neuromyelitis optica (Devic\u2019s syndrome)","volume":"53","author":"Wingerchuk","year":"1999","journal-title":"Neurology"},{"key":"10.1016\/j.msard.2026.107379_bib0024","doi-asserted-by":"crossref","first-page":"2114","DOI":"10.1056\/NEJMoa1901747","article-title":"Trial of satralizumab in neuromyelitis optica spectrum disorder","volume":"381","author":"Yamamura","year":"2019","journal-title":"N. Engl. J. Med."}],"container-title":["Multiple Sclerosis and Related Disorders"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S2211034826004153?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S2211034826004153?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2026,8,28]],"date-time":"2026-08-28T12:47:32Z","timestamp":1787921252000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S2211034826004153"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2026,9]]},"references-count":24,"alternative-id":["S2211034826004153"],"URL":"https:\/\/doi.org\/10.1016\/j.msard.2026.107379","relation":{},"ISSN":["2211-0348"],"issn-type":[{"value":"2211-0348","type":"print"}],"subject":[],"published":{"date-parts":[[2026,9]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"Discontinuing immunotherapy in aquaporin-4-IgG-seropositive neuromyelitis optica spectrum disorder: Relapse risk and disability outcomes after treatment withdrawal","name":"articletitle","label":"Article Title"},{"value":"Multiple Sclerosis and Related Disorders","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1016\/j.msard.2026.107379","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"\u00a9 2026 The Author(s). Published by Elsevier B.V.","name":"copyright","label":"Copyright"}],"article-number":"107379"}}